EN DE
Watch Republic Healthcare Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Republic Healthcare Ltd (8357) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Republic Healthcare Ltd stock HK$0.03, price HK$0.20, that is 85.1% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in Singapore · ISIN KYG7516A1022

RH Republic Healthcare Ltd logo Thin data Nov 3, 2026

Republic Healthcare Ltd

8357 · HK
Very expensive, weak quality

Our calculation puts a fair price 85% below what the stock costs today.

Quality 41/100
Fair value HK$0.0300 · Strongly overvalued (−85.1%)
Weak Growth (revenue 5y −10.8 %/yr in SGD)
Loss-making · -39.4% net margin (TTM)
Negative free cash flow
Trails peers (1/9)
Narrow moat 3/100 · thin data
Thin data
Watch Republic Healthcare Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$0.6500 HK$0.0520 Fair Value HK$0.0300 Apr 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.

How to read this chart

60‑month range HK$0.0520 – HK$0.6500 · fair‑value band HK$0.0200 – HK$0.0300 · the HK$0.2010 price screens above the HK$0.0300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.

Follow Republic Healthcare in your weekly email

Every Wednesday you see whether Republic Healthcare is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Republic Healthcare Limited, an investment holding company, operates a network of general practice medical clinics under the Dr. Tan & Partners (DTAP) brand in Singapore and the People's Republic of China. It operates through Medical Services and Education Services segments.

Show moreShow less

The company offers consultation, medical investigation, and treatment; men's, women's, and sexual health; health management; management advisory; and healthcare-related education and educational support services.

It also provides its services under the S Aesthetics Clinic (SAC) and California Metropolitan University (CMU) brands. Republic Healthcare Limited was founded in 2010 and is headquartered in Singapore.

Stock analysis

Republic Healthcare Ltd (8357) currently trades at HK$0.2010, while our model-based Fair Value estimate is HK$0.0300, 85% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: HK$0.0200 (bear) to HK$0.0300 (bull), the price of HK$0.2010 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Republic Healthcare Ltd reported revenue of 7.8M SGD in FY2025 versus 14.0M SGD in FY2021, a compound −13.4%/yr. Reported net income was −3.0M SGD in FY2025.

Key figures

Market cap HK$125M (≈ $16.0M) Micro · P/S ratio 14.5 · Net margin −37.8% · Return on equity −35.2% · Return on assets (EBIT) 1.5% (5-year average) · Operating margin −33.9% · Revenue (TTM) 8.6M SGD · Revenue growth (YoY) +11.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and 148% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at −85%, 8357 screens richer than that median.

Fair Value models

Bear HK$0.0200 Fair Value HK$0.0300 Bull HK$0.0300
Price HK$0.2010 · Downside -85.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) HK$0.0200 HK$0.0300 HK$0.0300 53
All 1 models by family
Asset-Based
NCAV (Graham) HK$0.0200 HK$0.0300 HK$0.0300 53

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 0
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 97
Debt, balance sheet and risk of trouble
Investment 75
Does it invest with discipline instead of growing at any price?
Low Volatility 23
How calm the share price moves, does not count
Price momentum 78
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 55
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−15.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−10.8%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
9.0% (2019) → −34.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

8357 screens overvalued: fair value 85% below the price. Compare with HCA Healthcare, Inc →

Compare Republic Healthcare Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 233 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −85.1% · Bottom 25%
Profitability
Return on assets −18.4% · Bottom 25%
Net margin (12 months) −39.4% · Bottom 25%
Operating margin (12 months) −33.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 11.8% · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/B 2.15× · Pricier than median
P/S (12 months) 2.39× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 34
FUTURE (revenue growth)59 · sector 30
PAST (return on equity)0 · sector 32
HEALTH (low debt)0 · sector 90
DIVIDEND (yield)0 · sector 39

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $23.40 $46.55 +99% vs 8357
Aier Eye Hospital Group 300015 ¥9.01 ¥10.88 +21% vs 8357
DaVita Inc DVA $191.35 $218.90 +14% vs 8357
HCA Healthcare, Inc HCA $494.99 $547.34 +11% vs 8357
Tenet Healthcare Corporation THC $283.33 $279.20 −1% vs 8357
Encompass Health Corporation EHC $137.54 $94.81 −31% vs 8357
IHH Healthcare Berhad 5225 7.70 MYR 5.23 MYR −32% vs 8357
Fresenius SE FRE €52.48 €34.77 −34% vs 8357
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,446 ₹5,234 −38% vs 8357
Dr. Sulaiman Al Habib Medical Services Group 4013 215.80 SAR 109.45 SAR −49% vs 8357

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Republic Healthcare Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Republic Healthcare Ltd Fair Value". https://www.fairvalue-calculator.com/stock/8357

Frequently asked questions

Is Republic Healthcare Ltd (8357) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of HK$0.0300 versus a price of HK$0.2010, about 85% lower (overvalued).
What is the fair value of 8357?
Our model-based fair value for Republic Healthcare Ltd is HK$0.0300 (as of Nov 3, 2026), built from audited fundamentals. The current price: HK$0.2010.
What is the quality score of 8357?
Republic Healthcare Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Republic Healthcare Ltd (8357)?
Our model-based price target is the fair value of HK$0.0300 (as of Nov 3, 2026) from 1 valuation models. Cautious scenario HK$0.0200, optimistic scenario HK$0.0300. It is a calculation from audited fundamentals, not an analyst target.
What is the Republic Healthcare Ltd stock forecast for 2026?
Our models put fair value at HK$0.0300, about 85% lower versus a price of HK$0.2010 (overvalued). Cautious scenario HK$0.0200, optimistic scenario HK$0.0300. The calculation is refreshed regularly with new filings.
What is the revenue of Republic Healthcare Ltd (8357)?
Republic Healthcare Ltd reported trailing-twelve-month revenue of about 8.6M SGD (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Republic Healthcare Ltd (8357)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Republic Healthcare Ltd it is HK$0.0300 per share (as of Nov 3, 2026), against a price of HK$0.2010. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Republic Healthcare Ltd stock overvalued or undervalued in 2026?
As of Nov 3, 2026, 8357 trades above its calculated fair value: price HK$0.2010, fair value HK$0.0300, a gap of about −85% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 8357?
No. The price is what the market pays today (HK$0.2010); the fair value is what the company's own numbers justify (HK$0.0300). For Republic Healthcare Ltd the two are HK$0.1710 per share apart. That gap is exactly why we show both numbers side by side.
How much is Republic Healthcare Ltd worth?
The market values Republic Healthcare Ltd at about HK$125M (market capitalisation, as of Nov 3, 2026). Per share that is HK$0.2010; our models calculate a fair value of HK$0.0300 per share.
What do the bullish and bearish scenarios say about 8357?
Our models span a range for Republic Healthcare Ltd: cautious scenario HK$0.0200, base HK$0.0300, optimistic HK$0.0300 per share (as of Nov 3, 2026, price HK$0.2010). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Republic Healthcare Ltd (8357)?
Balance-sheet figures for Republic Healthcare Ltd (as of Nov 3, 2026): return on equity −35.2%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 8357 from its 52-week high?
Republic Healthcare Ltd trades at HK$0.2010, about 26% below its 52-week high of HK$0.2700 and 148% above the low of HK$0.0810 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.0300 is for.
Which stocks are comparable to Republic Healthcare Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Republic Healthcare Ltd stock attractive at the current price?
The data as of Nov 3, 2026: price HK$0.2010, calculated fair value HK$0.0300 (−85%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 8357 calculated?
We run Republic Healthcare Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of HK$0.0300 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Republic Healthcare Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Republic Healthcare Ltd (8357)?
The closing price on Nov 6, 2026 was HK$0.2010. Our model-based fair value is HK$0.0300, about 85% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Republic Healthcare Ltd right now?
The price sits above even our optimistic bull case (HK$0.0300). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Republic Healthcare Ltd

How large is the market capitalisation of Republic Healthcare Ltd (8357)?
The market capitalisation of Republic Healthcare Ltd is HK$125M (≈ $16.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Republic Healthcare Ltd (8357)?
The price-to-sales ratio of Republic Healthcare Ltd is 14.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Republic Healthcare Ltd (8357)?
The net margin of Republic Healthcare Ltd is −37.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Republic Healthcare Ltd (8357)?
The return on equity (ROE) of Republic Healthcare Ltd is −35.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Republic Healthcare Ltd (8357)?
On an EBIT basis the return on assets of Republic Healthcare Ltd is 1.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Republic Healthcare Ltd (8357)?
The operating margin of Republic Healthcare Ltd is −33.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Republic Healthcare Ltd (8357)?
Revenue at Republic Healthcare Ltd is growing +11.8% versus a year earlier (3y avg −6.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Republic Healthcare Ltd (8357) generate?
The free cash flow of Republic Healthcare Ltd is −3.1M SGD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Republic Healthcare Ltd (8357) hold?
Republic Healthcare Ltd holds more cash than debt, 1.4M SGD net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Republic Healthcare Ltd in the live analysis

One click puts Republic Healthcare Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.